실데나필 복용 이후 발생한 청색시증에 대한 사례
A Case Report of Cyanopsia after Taking Sildenafil
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The emergence of phosphodiesterase (PDE) 5 inhibitors gave rise to the solution for erectile dysfunction, starting with the development of sildenafil. Although their efficacy in treating erectile dysfunction has been shown, the side effects of PDE5 inhibitors, especially sildenafil, must be taken into consideration. A 64-year-old man received 100 mg of sildenafil and experienced blue vision in both eyes; however, after a day or so, his symptoms improved. The symptoms disappeared when he stopped administering sildenafil, but reappeared when the medication was re-administered. Therefore, he discontinued sildenafil treatment and was prescribed udenafil instead. After that, visual adverse events no longer occurred. Causality assessment showed that in this case, sildenafil-induced cyanopsia was “certain” under the World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria and Korean causality assessment algorithm (Ver.2), and was “probable” according to the Naranjo scale. In addition, sildenafil also led to abnormal visual reactions in other cases. Sildenafil can also inhibit PDE6, which is present in retinal cells, unlike other PDE5 inhibitors. Thus, visual adverse reactions, such as blue vision, are the unique results of sildenafil, and other PDE5 inhibitors may be used to prevent them.
Abstract
The emergence of phosphodiesterase (PDE) 5 inhibitors gave rise to the solution for erectile dysfunction, starting with the development of sildenafil. Although their efficacy in treating erectile dysfunction has been shown, the side effects of PDE5 inhibitors, especially sildenafil, must be taken into consideration. A 64-year-old man received 100 mg of sildenafil and experienced blue vision in both eyes; however, after a day or so, his symptoms improved. The symptoms disappeared when he stopped administering sildenafil, but reappeared when the medication was re-administered. Therefore, he discontinued sildenafil treatment and was prescribed udenafil instead. After that, visual adverse events no longer occurred. Causality assessment showed that in this case, sildenafil-induced cyanopsia was “certain” under the World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria and Korean causality assessment algorithm (Ver.2), and was “probable” according to the Naranjo scale. In addition, sildenafil also led to abnormal visual reactions in other cases. Sildenafil can also inhibit PDE6, which is present in retinal cells, unlike other PDE5 inhibitors. Thus, visual adverse reactions, such as blue vision, are the unique results of sildenafil, and other PDE5 inhibitors may be used to prevent them.
참고문헌 (35)
- Feldman HA, "Impotence and its medical and psychosocial correlates : results of the Massachusetts Male Aging Study", J Urol, 151(1), pp.54~61 (1994)
- Wespes E, "EAU Guidelines on erectile dysfunction : an update", Eur Urol, 49(5), pp.806~815 (2006)
- Huang SA, "Phosphodiesterase-5 (PDE5) inhibitors In the management of erectile dysfunction", P T, 38(7), pp.407~419 (2013)
- "VIAGRA® Tablets 50 mg/ 100 mg (sildenafil citrate) 2014"[URL]
- "Cialis 10 mg (tadalafil) 2017"[URL]
- "Zydena 100 mg (udenafil)"[URL]
- "The use of the WHO-UMC system for standardized case causality assessment"[URL]
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30(2), pp.239~245 (1981)
- 홍경섭, "약물이상반응의 인과성 평가를 위한 한국형 알고리즘의 개발", Translational and Clinical Pharmacology, 10(2), pp.129~142 (2002), 대한임상약리학회
- Guler S, "Blue vision and sinus tachycardia : sildenafil citrate overdose", J Acad Emerg Med, 6, pp.87~89 (2015)
- Li Y-Y, "Visual impairment with possible macular changes after a high dose of sildenafil in a healthy young woman", Int J Ophthalmol, 11(2), pp.340~342 (2018)
- Yanoga F, "Sildenafil citrate induced retinal toxicity-electroetinogram, optical coherence tomography, and adaptive optics findings", Retin Cases Brief Rep, 12(Suppl 1), pp.S33~S40 (2018)
- Lue TF, "Erectile dysfunction", N Engl J Med, 342(24), pp.1802~1813 (2000)
- Burnett AL, "Nitric oxide in the penis : physiology and pathology", J Urol, 157(1), pp.320~324 (1997)
- Ignarro LJ, "Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle", Biochem Biophys Res Commun, 170(2), pp.843~850 (1990)
- Laties A, "Viagra(sildenafil citrate)and ophthalmology", Prog Retin Eye Res, 21(5), pp.485~506 (2002)
- Boolell M, "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction", Int J Impot Res, 8(2), pp.47~52 (1996)
- Corbin JD, "Cyclic GMP phosphodiesterase-5: target of sildenafil", J Biol Chem, 274(20), pp.13729~13732 (1999)
- Miller WH, "Evidence that cyclic GMP regulates membrane potential in rod photoreceptors", Nature, 280(5717), pp.64~66 (1979)
- Ames A, 3rd, "Metabolic flux of cyclic GMP and phototransduction in rabbit retina", J Physiol, 406, pp.163~179 (1988)
- Pugh EN, Jr., "Cyclic GMP and calcium: the internal messengers of excitation and adaptation in vertebrate photoreceptors", Vision Res, 30(12), pp.1923~1948 (1990)
- Lagnado L, "Signal flow in visual transduction", Neuron, 8(6), pp.995~1002 (1992)
- Ebrey T, "Vertebrate photoreceptors", Prog Retin Eye Res, 20(1), pp.49~94 (2001)
- Lolley RN, "Cyclic GMP accumulation causes degeneration of photoreceptor cells : simulation of an inherited disease", Science, 196(4290), pp.664~666 (1977)
- Ulshafer RJ, "Sensitivity of photoreceptors to elevated levels of cGMP in the human retina", Optom Vis Sci, 19(10), pp.1236~1241 (1980)
- Nivison-Smith L, "Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa", Exp Eye Res, 128, pp.43~56 (2014)
- Tsang SH, "Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase", Science, 272(5264), pp.1026~1029 (1996)
- Cote RH, "Characteristics of photoreceptor PDE(PDE6) : similarities and differences to PDE5", Int J Impot Res, 16(1), pp.S28~S33 (2004)
- Ballard SA, "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes", J Urol, 159(6), pp.2164~2171 (1998)
- Wallis RM, "Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro", Am J Cardiol, 83(5), pp.3~12 (1999)
- Wallis RM, "The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5", Nihon Yakurigaku Zasshi, 114(Suppl 1), pp.22~26 (1999)
- Taylor J, "Differences in side-effect duration and related bother levels between phosphodiesterase type 5inhibitors", BJU Int, 103(10), pp.1392~1395 (2009)
- "Full prescribing information for VIAGRA 2017"[URL]
- Kotera J, "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction", J Urol, 188(2), pp.668~674 (2012)
- Corbin JD, "Pharmacology of phosphodiesterase-5inhibitors", Int J Clin Pract, 56(6), pp.453~459 (2002)